Why is "Afamelanotide" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-30 08:51:16
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria. It is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating hormone. It is administered as subcutaneous implant.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Clinuvel Completes Enrollment in Phase III Afamelanotide Vitiligo Trial - Dermatology Times
-
Scenesse quickly calms burning light pain for 9-year-old with EPP - Porphyria News
-
Clinuvel Recruits 200 Patients in Phase III Vitiligo Trial - The Clinical Trial Vanguard
-
Clinuvel reports breakthrough against UV damage in skin DNA repair study using afamelanotide - smallcaps.com.au
-
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 - GlobeNewswire
-
CLINUVEL’s SCENESSE demonstrates promising results in vitiligo patients - Biotech Dispatch
-
Afamelanotide tested as a new treatment for vitiligo – Vitiligo Clinic - umassmed.edu
-
Exploring Afamelanotide for Vitiligo: Insights into the CUV 105 Phase 3 Clinical Trial - Dermatology Times
-
NICE won't budge on rejection of rare disease drug - pharmaphorum
-
Clinuvel reports data from xeroderma pigmentosum therapy trial - Clinical Trials Arena
-
Afamelanotide plus UV-B phototherapy effective for vitiligo - 2 Minute Medicine
-
This ‘Barbie tanning drug’ creates a ‘summer glow’. But is it worth the risk? - SMH.com.au
-
Clinuvel Pharmaceuticals offers up novel drug to combat rare genetic disease following FDA approval - smallcaps.com.au
-
How a patient helped shape a treatment for a rare skin disorder - Pharmaceutical Technology
-
Scenesse improves life quality in EPP adults: Real-world study - Porphyria News
-
Clinuvel Showcases AI-Powered Vitiligo Assessment Tool at AAD Conference - smallcaps.com.au
-
Scenesse may help reduce liver damage in EPP patients: Study –... - Porphyria News
-
Clinuvel Pharmaceuticals reaches patient recruitment milestone ahead of Phase III Scenesse vitiligo trial - smallcaps.com.au
-
Supplements essential for common vitamin D deficiency in EPP: Study - Porphyria News
-
People with porphyrias EPP, XLP see delayed diagnosis, high healthcare costs - Porphyria News
-
Scenesse increases sunlight tolerance in EPP, XLP patients: Study - Porphyria News
-
Scenesse Increases Sunlight Tolerance in Adults With EPP, Real-world Data Show - Porphyria News
-
Dersimelagon reduces symptomatic disease in erythropoietic protoporphyrias - 2 Minute Medicine
-
Scenesse Treatment May Improve Life Quality for EPP Patients: Study - Porphyria News
-
Scenesse is now available under VA healthcare program in US –... - Porphyria News
-
Vitiligo treatment holds promise for restoring skin pigmentation - EurekAlert!
-
Scotland first in UK to approve 'take at home' MS drug - BBC
-
CLINUVEL progresses vitiligo treatment program - GlobeNewswire
-
No, you don’t need the ‘Barbie drug’ to tan, whatever TikTok says. Here’s why melanotan-II is so risky - The Conversation
-
US FDA pathway opens to SCENESSE® following Fast Track designation for treatment of EPP - CNBC
-
Oral Drug Improves Sunlight Tolerance in Genetic Photosensitivity Disorders - MedPage Today
-
Photoprotection Finds Its Place in the Sun - Genetic Engineering and Biotechnology News
-
FDA Approves Clinuvel’s Scenesse for Extreme Light Sensitivity - BioSpace
-
The Tanning Drug: What Your Patients Should Know About Melanotan II - Healthgrades
-
Clinuvel gets approval in US for rare skin disorder drug Scenesse - pharmaphorum
-
Sunless tanning? There’s a product in the works - Financial Times
-
I Injected Myself For Tanned Skin & I Have So Many Regrets - Refinery29
-
First drug for rare sun disease recommended for approval in Europe - The Pharmaceutical Journal
-
What are ‘melanotan’ injections? Explaining the controversial tanning drug - Dazed
-
Clinuvel starts US phase III trial of SCENESSE - BioSpectrum Asia
-
Clinuvel's Scenesse being trialled in HHD - Lab + Life Scientist
-
Melanin injections are the dangerous way celebrities are trying to score a tan - Glamour South Africa
-
Cardiex up 15pc after healthy sales update - ntnews.com.au
-
Clinuvel success in Scenesse trial - Lab + Life Scientist
-
Clinical Trials 101: How to spot a clinical trial with a strong chance of getting a drug to market - Stockhead
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.